Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $1.1 million.

  • Artiva Biotherapeutics' Change in Accured Expenses fell 6392.65% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year decrease of 38445.38%. This contributed to the annual value of -$659000.0 for FY2024, which is 2774.12% up from last year.
  • Per Artiva Biotherapeutics' latest filing, its Change in Accured Expenses stood at $1.1 million for Q3 2025, which was down 6392.65% from -$550000.0 recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Change in Accured Expenses ranged from a high of $3.1 million in Q3 2024 and a low of -$3.0 million during Q1 2024
  • In the last 3 years, Artiva Biotherapeutics' Change in Accured Expenses had a median value of -$359000.0 in 2023 and averaged -$137444.4.
  • Examining YoY changes over the last 5 years, Artiva Biotherapeutics' Change in Accured Expenses showed a top increase of 96406.69% in 2024 and a maximum decrease of 79370.63% in 2024.
  • Over the past 3 years, Artiva Biotherapeutics' Change in Accured Expenses (Quarter) stood at $143000.0 in 2023, then tumbled by 793.71% to -$992000.0 in 2024, then surged by 212.8% to $1.1 million in 2025.
  • Its Change in Accured Expenses was $1.1 million in Q3 2025, compared to -$550000.0 in Q2 2025 and -$931000.0 in Q1 2025.